Vitrakvi (Larotrectinib)

Vitrakvi (Larotrectinib)

Vitrakvi

Larotrectinib

Capsules: 25 mg, 100 mg 

Bayer Pharmaceuticals

Medical Use

Vitrakvi is a kinase inhibitor used for treating adult and pediatric patients with solid tumors that:

  • -Have an NTRK gene fusion without any known resistance mutations,
  • -Are metastatic or where surgical removal would cause significant morbidity,
  • -Have no satisfactory alternative treatments or have progressed after previous treatments.

Recommended Dosage:

  • -For adults and pediatric patients with a body surface area (BSA) of at least 1.0 m²: 100 mg orally twice daily.
  • -For pediatric patients with a BSA less than 1.0 m²: 100 mg/m² orally twice daily.

Take Vitrakvi capsules with or without food, swallowing them whole with water. Do not chew or crush the capsules. If a dose is missed, do not take it within six hours of the next scheduled dose. If vomiting occurs after taking a dose, take the next dose at the regular time.